Low-Dose r-ATG vs Basiliximab in Low-Risk Living-Donor Kidney Transplantation: Outcomes in Acute Rejection, Graft Function, and Infections

Nam Ho; Thu Thi Nguyen; Nam Van Do; Chi Tam Nguyen; Su Xuan Hoang; Khanh Vo Ngoc Hoang; Trung Dinh Ngo

doi:10.12659/AOT.949942

21 October 2025 : Original article

Low-Dose r-ATG vs Basiliximab in Low-Risk Living-Donor Kidney Transplantation: Outcomes in Acute Rejection, Graft Function, and Infections

Nam Ho

^{ABDEF 1}, Thu Thi Nguyen^{BCDF 1}, Nam Van Do^{BCD 1}, Chi Tam Nguyen

^{BEF 1}, Su Xuan Hoang^{DEF 2}, Khanh Vo Ngoc Hoang^{BEF 3}, Trung Dinh Ngo^{ABDEF 1*}

DOI: 10.12659/AOT.949942

Ann Transplant 2025; 30:e949942

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 2 Kaplan-Meier analysis showed no significant difference in rejection-free survival between low-dose r-ATG and basiliximab recipients (log-rank P=0.794). Created using IBM SPSS Statistics (version 27.0; IBM Corp., Armonk, NY, USA).

Back to the Article

Low-Dose r-ATG vs Basiliximab in Low-Risk Living-Donor Kidney Transplantation: Outcomes in Acute Rejection, Graft Function, and Infections

Your Privacy